Xenon Pharmaceuticals Inc.: Polar Capital Holdings Plc discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Polar Capital Holdings Plc disclosed a stake exceeding 5% in Xenon Pharmaceuticals Inc. via a Schedule 13G filing with the SEC (accession 0001172661-26-005106). The filing signals that the asset manager has crossed the 5% beneficial ownership threshold, making it a reportable major shareholder in the clinical-stage biopharmaceutical company. The exact number of shares and percentage held were not specified in the disclosure headline. Investors will watch for further detail in the full filing and any subsequent 13G amendments that clarify the size and nature of Polar Capital's position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Polar Capital Holdings Plc, Xenon Pharmaceuticals Inc.